d-FENSE

Porcine Circovirus Vaccine  

Type 2, Killed Baculovirus Vector  

Details

Having first been identified in 2012, today porcine Circovirus Type 2d (PCV2d) is the predominant genotype circulating in the United States, accounting for more than 90% of PCV2 infections.1-2

 

An extensive body of research has demonstrated that Ingelvac CircoFLEX®, a PCV2a-based vaccine, can provide heterologous cross-protection against PCV2d.3-7 In most cases, producers can rely on this trusted vaccine to protect their herds from the harmful effects of porcine circovirus associated disease (PCVAD). But in some scenarios, such as a PCV2d infection along with severe co-infections, prevention of PCV2d’s clinical impact calls for a different approach.

 

That’s why Boehringer Ingelheim introduced d-FENSE, the swine industry’s first PCV2d-based killed baculovirus vector vaccine. It is designed to provide a different approach for extreme PCVAD presentations.

Features & Benefits

  • Onset of immunity within two weeks of vaccination. 
  • Single-dose (1 mL) PCV2 vaccine.  
  • Can be administered to pigs 3 weeks of age and older. 
  • Provides a duration of immunity of at least four months. 
  • Low risk of adverse reactions and stress on pigs due to one-dose administration. 
  • PQA® Plus friendly. 
  • Contains ImpranFLEX®, an effective, aqueous-based (non-oil) polymer adjuvant. 
  • Flexible vaccination scheduling. 
  • Reduces PCV2 viremia. 
Dosage & Administration

Shake well before use. Using aseptic technique, administer a single 1-mL dose by intramuscular injection. 

Resources
Safety

d-FENSE Safety Data Sheet (SDS)

 

Uses

 

  • For vaccination of healthy, susceptible pigs 3 weeks of age or older as an aid in the prevention of lymphoid depletion, inflammation and colonization of lymphoid tissue. 
  • As an aid in reduction of the magnitude of viremia associated with porcine circovirus Type 2 (PCV2d).  

 

Precautions

 

  • Store out of direct sunlight at 35° – 46°F (2° – 8°C). Do not freeze. Use entire contents when first opened.
  • Do not vaccinate within 21 days before slaughter.
  • In case of anaphylactic reaction, epinephrine is symptomatic treatment.
  • This product has not been tested in pregnant animals.
  • In case of human exposure, contact a physician.  

ImpranFLEX® Adjuvant

IMPRANFLEX is a proprietary water-based, sponge-like matrix adjuvant found in all FLEX Family vaccines that offers the following advantages:  

  • Does not contain and is not derived from any material of plant or animal origin
  • 100 percent oil free 
  • Low viscosity and good syringeability 
  • Very safe for farm staff and animals 
  • Less stressful for the animals  
References

1 Segalés J, Allan G, Domingo M. Circoviruses. Zimmerman J, Karriker LA, Ramirez A, et al., eds. Diseases of swine (11th Edition) 2019;473–487.

2 Madson D. Porcine circoviruses: Are changes occurring?, in Proceedings. AASV 50th Annual Meeting 2019;5–8.

3Payne B, Jacobs, Dvorak C, et al. PCV2 vaccine cross-protection: Identification of sequences in successfully vaccinated field cases, in Proceedings. AASV Annual Meeting 2016;202–206.

4 Fano E, Schaefer N, Schmaling E, et al. Comparison of efficacy between two PCV2 vaccination protocols under PCV2d field exposure, in Proceedings. AASV Annu Meet 2017;95–97.

5 Fano E et al. Comparison of efficacy between two PCV2 vaccines under PCV2d experimental exposure, in Proceedings. AASV 2021.

6 Philips R, Fano E, Schmaling E, Edler R. A severe PRDC challenge and the effect of a trivalent PRDC vaccine for PCV2, Mhp and PRRS. Boehringer Ingelheim Vetmedica, Inc., Health Management Center (HMC), Field Research Services. 2018.

7 Friedrich R, Patterson AR, Johnson W, et al. Efficacy of porcine circovirus Type 2a– and 2d– based vaccines following PCV2 challenge. J Vaccines Vaccination 2019;10(2):1–5.

Trademarks

IMPRANFLEX® and INGELVAC CIRCOFLEX® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2022 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved.

US-POR-0028-2022-V2